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ABSTRACT
Major regional variations in the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) are
observed across Europe. This study investigated hospital MRSA prevalence in relation to patterns of
antimicrobial use and infection control policies in an observational, cross-sectional study that used
retrospective data from 2001 and linear regression to model relationships. MRSA prevalence (median
20.8%, n = 173 hospitals) and antimicrobial consumption (median 55.2 deﬁned daily doses ⁄ 100 bed-
days, n = 140 hospitals) both varied signiﬁcantly according to geographical region (p <0.001). MRSA
prevalence and antimicrobial consumption data were provided by 128 hospitals, and showed a strong
statistical relationship between macrolide use and MRSA prevalence. Use of (i) third-generation
cephalosporins, (ii) all antimicrobial agents, and (iii) all antimicrobial agents except glycopeptides was
also associated with MRSA prevalence. Up to 146 hospitals provided data on MRSA prevalence and key
infection control parameters. Adjusted linear regression modelling provided strong evidence that
infection control policy recommendations associated with lower MRSA prevalence rates were (i) use of
alcohol-based solutions for hand hygiene (mean difference 10.3%, 99% CI 1.2–10.3), and (ii) placement
of MRSA patients in single rooms (mean difference 11.2%, 99% CI 1.4–20.9). Hospitals with problems in
implementing isolation policies had higher resistance levels (mean difference 12%, 99% CI 3.8–20.1).
Additional recommendations showed less evidence of association with a low MRSA prevalence.
Overall, this study highlighted signiﬁcant associations between MRSA prevalence, antimicrobial use
and various key infection control parameters, all of which showed signiﬁcant individual variations
according to geographical region.
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INTRODUCTION
Although there are many antibiotic-resistant
microorganisms that cause healthcare-associated
infections, it is the global rise in rates of methi-
cillin-resistant Staphylococcus aureus (MRSA) that
is currently causing most alarm. MRSA-associ-
ated morbidity, mortality and healthcare costs
are escalating [1], and increasing resources are
being invested in designing strategies to control
and eradicate this organism. However, despite
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this investment, there has been a widespread
failure to control MRSA, largely because of the
frequent failure of hospitals to implement effect-
ive control measures [2,3]. This may be associ-
ated with an absence of substantive evidence to
inform guidelines, which are often developed
solely on the basis of expert opinion. It is the
opinion of some that there may never be
sufﬁcient data to provide evidence for speciﬁc
infection control interventions, partly because of
a lack of funding, and also because of feasibility
issues and ethical dilemmas [4]. With this in
mind, modelling studies provide a virtual work-
bench for interpreting observational data, and
provide a powerful methodology for designing
future studies [1].
Successful MRSA control must be based on a
fundamental understanding of the complex fac-
tors responsible for creating and exacerbating the
problem. All too often, intervention studies focus
on infection control aspects of the problem while
neglecting the role played by (mis)use of antibi-
otics. This may be related to the fact that relatively
few studies have quantiﬁed the relationships
between antimicrobial use and MRSA rates.
MRSA control is a multifactorial issue requiring
a multifaceted package of prevention and control
measures. Single measures are often studied, but
each alone may have little impact on MRSA.
Conversely, where a multifactorial approach has
been used, the precise impact of any single
measure often cannot be determined [5]. Limited
quantitative measures using both approaches
have been described previously.
The present study used statistical modelling to
explore hospital-level relationships among
MRSA prevalence, antibiotic use and infection
control policies and practices across Europe in
2001, with the aim of recommending how Euro-
pean hospitals can better control MRSA. This
study is the largest and most comprehensive
investigation of these associations performed to
date.
MATERIALS AND METHODS
This Concerted Action research project was funded by the
European Commission and was carried out under the auspices
of four study groups of the European Society of Clinical
Microbiology and Infectious Diseases (ESCMID), i.e., the
ESCMID Study Groups on Antibiotic Policies (ESGAP), Anti-
microbial Resistance Surveillance (ESGARS), Nosocomial
Infections (ESGNI) and Epidemiological Markers (ESGEM).
The short title of the project was Antibiotic Resistance;
Prevention and Control. Herewith, the project will be referred
to by its acronym, ARPAC.
Data collection
This was an observational, retrospective, cross-sectional study,
and data were collected via postal and online questionnaires.
During 2002, all ESCMID members were invited to participate
in the study by completing a screening questionnaire. To be
eligible for inclusion in the study, individuals had to work in a
European hospital and be able to provide data for 2001
concerning the prevalence of speciﬁc antimicrobial-resistant
bacterial pathogens, antimicrobial susceptibility testing meth-
ods, antimicrobial use, antibiotic policies and infection control
policies. Data from paediatric hospitals were excluded.
Resistance prevalence data
Data concerning antimicrobial susceptibility testing methods
and the prevalence of nine ‘alert’ resistant microorganisms
relevant to the hospital setting, of which MRSA was one, were
collected by questionnaire. Each hospital was asked to detail
the number of S. aureus isolated, the number of S. aureus
isolates tested against methicillin or oxacillin, and the numbers
of isolates found to be susceptible (S), intermediately-resistant
(I) and resistant (R) to methicillin ⁄ oxacillin for all hospitalised
patients during 2001. Resistance prevalence was calculated as
(I + R) ⁄ (S + I + R) · 100. The project protocol stated that only
the ﬁrst isolate per patient of a given species in 2001 should be
included; i.e., all duplicates should be excluded [6]. Informa-
tion on whether duplicates were excluded and the method
adopted was collected.
Antimicrobial usage data
Antimicrobial usage data for 2001 were collated, primarily
using the ABC Calc Excel spreadsheet provided for the
purpose [7]. Antimicrobial usage data were expressed as
deﬁned daily doses (DDDs) ⁄ 100 occupied bed-days (BD),
using the Anatomical Therapeutic Compound (ATC) classiﬁ-
cation system and DDDs deﬁned by the WHO [8]. Data were
collected for the J01 ATC class, which comprises antibacterial
agents for systemic use.
The project created a hypothesis-built, analytical multiple-
group ecological study design, which allowed measurement of
the total effect of antibiotic exposure on antimicrobial resist-
ance and the demonstration of associations between speciﬁc
classes of antimicrobial agent according to biological mecha-
nisms of resistance. Thus, relationships were explored between
MRSA prevalence and all antimicrobial agents in the J01 class,
and also J01 antimicrobial agents minus the glycopeptides
(J01XA), cephalosporins (J01DA), third-generation cephalospo-
rins (J01DD), ﬂuoroquinolones (J01MA), macrolides (J01FA)
and aminoglycosides (J01G).
Infection control policies
Data pertaining to infection control policies were collected in
the following categories: infection control management;
screening for patients with alert organisms; incidence of alert
organisms; infection control precautions recommended for
speciﬁc alert organisms; isolation and standard infection
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control precautions; decolonisation ⁄decontamination;
audit ⁄ feedback; education and stafﬁng levels; and intensive-
ness of care. Forty-eight questions generated over 400
variables, which will be reported elsewhere. Seventeen key
infection control questions were identiﬁed a priori for multi-
variate modelling.
Statistical analysis
Data were entered into a Microsoft Access database and
analysis was conducted using SPSS v.12.0 for Windows (SPSS
Inc., Chicago, IL, USA). Data were presented according to ﬁve
European geographical regions, deﬁned using a modiﬁed
standard reference system agreed by the ARPAC Steering
Group (Table 1). To ensure reasonable precision in calculating
the MRSA prevalence for each hospital, only hospitals with
>20 S. aureus isolates tested against methicillin ⁄oxacillin were
included.
Median and inter-quartile rangeswere calculated to describe
MRSA prevalence and antimicrobial use. Mann–Whitney and
Kruskal–Wallis tests were adopted for comparisons of the
variables according to geographical regions and hospital char-
acteristics. Spearman rank correlations were computed to
investigate the relationship between resistance and consump-
tion, and multiple linear regression was adopted to explore the
relationship between MRSA prevalence and infection control
policy recommendations a priori (see Results), while adjusting
for potential confounding factors. Three models are presented,
two of which were adjusted. The ﬁrst of the adjusted models
took into account variations in hospital size, teaching hospital
status, exclusion of duplicate isolates in the MRSA prevalence
data, and the number of long-stay, paediatric and intensive care
unit beds, expressed as a proportion of total bed numbers. In
addition to these factors, the second model adjusted for the
geographical region of the hospital as a proxy for regional
variation inMRSAresistance rates. Since thenumberofS. aureus
isolates tested varied among hospitals, a weighted analysis was
carried out, giving greaterweight to hospitalswithmore precise
measurements of resistanceprevalence. For all analyses, p <0.01
was considered to indicate statistical signiﬁcance.
RESULTS
In total, 263 European hospitals expressed an
interest in participating in the study and provided
basic demographical data. These hospitals were in
34 countries, including Israel (eligible for inclu-
sion because of a bilateral scientiﬁc cooperation
agreement for European Commission-funded
studies). Of these, 204 hospitals in 32 European
countries subsequently submitted at least one
further requested dataset (Table 1).
MRSA prevalence data were supplied by 173
(65.8%) hospitals (Fig. 1). Data from a further
three hospitals were excluded because they report-
ed testing <20 isolates annually. For the 173
hospitals, the median MRSA prevalence in 2001
was 20.8% (inter-quartile range 6.4–35.8%), with
minimum and maximum values of 0% and 69%,
respectively. There was strong evidence of sig-
niﬁcant variation in resistance levels according to
geographical region (p <0.001) (Fig. 1). There was
weak evidence of a lower prevalence of resistance
in larger hospitals, but no evidence to suggest that
case-mix, teaching status and exclusion of dupli-
cates were associated with resistance prevalence.
In total, 140 (53.2%) hospitals provided valid
antimicrobial usage data for 2001, with a
median total antimicrobial use of 55.2 DDD ⁄ 100
BD (inter-quartile range 39.6–72.6 DDD ⁄ 100 BD).
There was strong evidence of variation in total
usage and in use of the major classes of
antimicrobial agent according to geographical
region (p <0.001) (Fig. 2). There was no evidence
to suggest that hospital size, case-mix and
teaching status were associated with J01 use.
Overall, 128 hospitals provided valid MRSA
prevalence and antimicrobial usage data. Scatter-
plots of these data displayed a weak-to-moderate
positive linear relationship. Moderate correlations
between MRSA prevalence and use of all antibi-
otics (J01), all antibiotics minus glycopeptides
(J01 ) J01XA) and third-generation cephalospo-
rins (J01DD) were found (Table 2).
Table 1. Geographical classiﬁcation
of European countries and number
of hospitals participating in the
ARPAC project
Northern
Europe
n = 24
Western
Europe
n = 62
Central ⁄ eastern
Europe +
Baltic States
n = 49
South-east
Europe
n = 14
Southern
Europe and
Israel
n = 55
Denmark (n = 6) Austria (n = 6) Bulgaria (n = 8) Albania (n = 0) Greece (n = 11)
Finland (n = 0) Belgium (n = 21) Czech Republic (n = 3) Bosnia (n = 2) Israel (n = 3)
The Netherlands (n = 9) France (n = 7) Estonia (n = 2) Croatia (n = 7) Italy (n = 10)
Norway (n = 4) Germany (n = 11) Hungary (n = 11) Macedonia (n = 1) Malta (n = 1)
Sweden (n = 5) Luxembourg (n = 0) Latvia (n = 2) Yugoslavia (n = 4) Portugal (n = 3)
Switzerland (n = 5) Lithuania (n = 3) Spain (n = 13)
UK (n = 12) Poland (n = 6) Turkey (n = 14)
Romania (n = 3)
Russia (n = 1)
Slovakia (n = 5)
Slovenia (n = 5)
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Table S1 (see Supplementary material) presents
the weighted adjusted analysis for MRSA preval-
ence according to antimicrobial use. By univariate
analysis, all antimicrobial agents (J01), all (J01)
minus glycopeptides (J01XA), the third-genera-
tion cephalosporins (J01DD) and macrolides
(J01FA) accounted for 15%, 15%, 16% and 17%
of the variation in resistance, respectively. After
removal of the variation in MRSA prevalence
caused by the confounding factors listed in Table
S1, a signiﬁcant association with macrolide use
was found (r = 0.67; p <0.001). An increase of
1 DDD ⁄ 100 BD was associated with an average
increase in MRSA prevalence of 1.6%
(95% CI 0.4–2.9).
A maximum of 146 hospitals provided valid
MRSA prevalence data and data for the 17 key
infection control parameters identiﬁed a priori
(Tables S1–S7; see Supplementary material). The
unadjusted model provided evidence to suggest
that six of these parameters were associated with
MRSA prevalence: (i) a system to automatically
inform the infection control team when a patient
with MRSA was identiﬁed; (ii) screening of
healthcare workers for MRSA carriage; (iii)
screening of patients for MRSA carriage; (iv)
0
10
20
30
40
50
60
70
SouthSouth-eastCentre / eastWestNorth
%
 M
R
SA
 
n = 18 n = 56 n = 46 n = 11 n = 42
European Region
Fig. 1. Prevalence of methicillin-
resistant Staphylococcus aureus
(MRSA) according to geographical
region, showing median, inter-quar-
tile range, and minimum and maxi-
mum values.
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Fig. 2. Antimicrobial use according
to geographical region, showing
median, inter-quartile range, and
minimum and maximum values.
DDD, deﬁned daily dose.
Table 2. Relationship between median methicillin-resist-
ant Staphylococcus aureus prevalence (%) and antimicrobial
use (deﬁned daily doses ⁄ 100 bed-days)
Antibiotic class
(ATC classiﬁcation code)
No. of
hospitals
Unadjusted
Spearman’s rank
correlation rs p value
All antibiotics (J01) 128 0.262 0.003
All antibiotics minus
glycopeptides (J01–J01XA)
128 0.258 0.003
Cephalosporins (J01DA) 128 0.197 0.023
Third-generation
cephalosporins (J01DD)
128 0.387 <0.001
Fluoroquinolones (J01MA) 128 0.206 0.02
Macrolides (J01FA) 128 0.200 0.02
Aminoglycosides (J01G) 128 0.149 0.09
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isolation of MRSA patients (excluding those with
only nasal carriage) in single rooms; (v) the use of
alcohol-based solutions for cleaning the non-
soiled hands of healthcare workers; and (vi) the
perception that a hospital had problems imple-
menting infection control policies (Tables S5–S7;
see Supplementary material). The most striking
differences in MRSA prevalence were seen
between hospitals that did and did not recom-
mend the use of alcohol-based hand-rub solutions
for healthcare workers with non-soiled hands (on
average, 23.7% and 14.2% MRSA, respectively)
(Table S2; see Supplementary material).
Multiple linear regression was applied to the
data to model the relationships between individ-
ual infection control variables and resistance,
with adjustment for potential confounding fac-
tors. The ﬁrst adjusted model highlighted associ-
ations between MRSA prevalence and seven
infection control parameters, three of which were
not identiﬁed in the unadjusted model, namely (i)
the number of infection control nurses per 1000
beds, and the use of (ii) gloves and (iii) gowns by
healthcare workers caring for MRSA-positive
patients (excluding those with only nasal car-
riage). After adjusting further for geographical
variation, the single strong predictor that
remained was the use of alcohol-based hand
rubs. Those hospitals that did not make this
recommendation had, on average, 9.5% more
MRSA.
DISCUSSION
It is reassuring that many of the factors that were
found to be associated with MRSA prevalence
have been described individually, to a degree, in
previous studies. To our knowledge, no previous
investigation has systematically described vari-
ation in these factors or variations in their associ-
ation with MRSA prevalence across Europe or
other parts of the world. It has been demonstrated
repeatedly that compliance of healthcare workers
with hand disinfection policies is the cornerstone
of infection prevention [9], combined with other
factors, e.g., isolation of patients in single rooms
[10], use of protective clothing by healthcare
workers [10], avoidance of understafﬁng [11],
education, improvement of compliance with
infection control, enforcement of barrier precau-
tions [5], and a sufﬁcient number of infection
control nurses [2].
Guidelines for the control of MRSA in hospitals
rarely include information on controlling the use
of antimicrobial agents, possibly because there are
still relatively few data that quantify the relation-
ships between use of antimicrobial agents and
MRSA rates, especially in outbreak situations.
Several methods for quantifying antimicrobial use
exist [12]. The DDD approach has been criticised
because the DDD does not always reﬂect the
actual dose given in clinical practice; nevertheless,
this method has become the standard for bench-
marking among different institutions and geo-
graphical areas [12]. Available reports provide
evidence that cephalosporin, ﬂuoroquinolone and
macrolide exposure, to which most MRSA clones
are consistently resistant, are all patient risk-
factors for MRSA infection or colonisation [13–16]
and ecological risk-factors [17–20] for high MRSA
prevalence. Temporal data show that variations in
the use of these speciﬁc antibiotic classes always
precede ﬂuctuations in MRSA rates [17,20]. In the
fully adjusted model, no evidence was found to
suggest an association between ﬂuoroquinolone
use andMRSA prevalence. The association report-
ed previously between ﬂuoroquinolones and
MRSA may not be generalisable across Europe,
since the studies that suggested this association
were restricted to the USA, which uses signiﬁ-
cantly more of this antimicrobial class, and to the
UK, Belgium, France and Germany [13–17].
The fact that this was a quantitative, multivar-
iable statistical modelling study spanning the
whole of Europe allows its conclusions to be
generalised to a greater degree to hospitals across
the continent than those of most previous studies,
which have been limited to single hospitals or
countries. The strengths of this collaborative pan-
European study include the large sample of
recruited hospitals, rigorous, piloted data collec-
tion methods, and high-quality data obtained
from participating hospitals. However, it must be
acknowledged that the participating hospitals
were self-selecting, which increases the risk of
response bias, and that coverage was sparse
in some countries. Ideally, a full listing of all
acute-care hospitals in Europe would provide a
sampling frame for random selection of eligible
hospitals, but no such list exists. Country-level
hospital data were obtained from EUROSTAT
(http://www.euro.who.int/) to assess the extent
of the European coverage attained in the sample
of hospitals. The crude estimated coverage of
MacKenzie et al. MRSA in European hospitals 273
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 269–276
European acute-care beds was estimated to be
10% or less per country; however, this is likely to
be an underestimate, as the EUROSTAT denom-
inator value often included psychiatric, long-stay
and community beds. Despite this disappointing
coverage, the prevalence data gathered were
comparable with those gathered by the European
Antimicrobial Resistance Surveillance System
(EARSS) [21].
The present study used MRSA prevalence (the
proportion of clinical S. aureus isolates that were
methicillin-resistant) as the principal outcome
indicator. For the purposes of inter-hospital com-
parison, a better outcome measure would have
been the number of new cases of hospital-
acquired MRSA per patient-day of hospitalisa-
tion, as this would assess more speciﬁcally the
risk of acquiring MRSA during hospitalisation
and is more sensitive to control measures. How-
ever, it was not possible to use this outcome
measure in the present study, as a large propor-
tion (60%) of participants were unable to provide
this set of incidence data.
The multifactorial approach of this study has,
inevitably, introduced important confounding
factors. For example, the precise reasons for the
geographical variations in MRSA prevalence are
unclear, but may very well be related to differ-
ences in infection control practice and antimicro-
bial prescribing habits, both of which were also
found to vary signiﬁcantly according to geo-
graphical region, or could be explained by resid-
ual confounding. Adjustment for geographical
variation in the second adjusted model may have
over-adjusted, and thereby masked, the effect of
antimicrobial use and infection control policy
recommendations on MRSA prevalence. The des-
criptive design of the study does not allow these
factors to be separated. However, if infection
control policy recommendations or antimicrobial
use can explain a signiﬁcant proportion of vari-
ability following adjustment for geographical
location, it is possible to be conﬁdent that these
are genuinely independent predictors. The true
measurement of effect probably falls somewhere
between the two adjusted models.
The ﬁndings of this study provide fundamental
evidence to inform future research. Rigorously
designed studies should be developed to test the
value of introducing signiﬁcant interventions
identiﬁed by the ARPAC study. In the meantime,
the ﬁndings suggest that wider implementation of
the highlighted control measures may lead to
more successful control of MRSA in many Euro-
pean hospitals. There are many expert opinions as
to which speciﬁc constituents should be included
in an overall hospital-based MRSA control strat-
egy. An all-inclusive strategy is essential, but is
difﬁcult to implement, and different elements will
have varying efﬁcacies in different settings. The
present study is the largest and most in-depth
investigation into the factors associated with
MRSA in Europe, and its ﬁndings therefore
provide high-priority, ﬁrst-line action points to
address the problem. Thus, the principal concern
of hospitals should be to make alcohol-based
hand disinfectants universally available and to
rigorously implement their use. It should also be a
fundamental requirement for hospitals to screen
patients for MRSA carriage and infection by the
most rapid and cost-effective methods available.
Although the present study supports the screen-
ing of staff, this is a more contentious issue and
may be more difﬁcult to implement. Once a
patient is identiﬁed as having MRSA, a system
should be put in place to inform the infection
control team automatically. Ideally, the patient
should then be isolated and cared for with barrier
precautions. The availability of single rooms for
this purpose is highly variable, but the provision
of such facilities should be a strategic goal of
hospital managers. The role of antibiotic use in
driving the MRSA problem should be given
greater exposure, and the appropriate use of key
antibiotic classes should be monitored more
closely [17]. The creation of an appropriate MRSA
control strategy should be a strategic priority for
hospital chief executives, who should facilitate its
implementation and ensure that there are no
barriers to impede its success. Many of the
relevant issues are common to basic hygiene
principles and control of all healthcare-associated
infections.
Finally, while there would be no MRSA with-
out antimicrobial use, it is clear that antimicrobial
agents must remain as a backbone of modern
medicine. It is therefore essential that unnecessary
use of antimicrobial agents must be minimised,
both to reduce the pressure that maintains MRSA
and helps its spread, and to reduce the prospect
of further resistance developing. The present
study has highlighted signiﬁcant associations
between MRSA prevalence, antimicrobial use
and various key infection control parameters, all
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of which showed signiﬁcant individual variations
according to geographical region. These ﬁndings
should help inform future, evidence-based
research into antimicrobial resistance.
ACKNOWLEDGEMENTS
We are grateful to the hospitals that participated in the
project. The ARPAC project was supported by DG Research
of the European Commission (Concerted Action project
number QLK2-CT-2001-00915). All researchers are independ-
ent of the funding body. The information contained in this
publication does not necessarily reﬂect the opinion or the
position of the European Commision. F. M. MacKenzie and I.
M. Gould are members of ESGAP, M. J. Struelens is a
member of ESGNI, and H. Goosens is a member of ESGARS.
F. M. MacKenzie was supported by ESGAP to write this
manuscript.
SUPPLEMENTARY MATERIAL
The following supplementary material is avail-
able for this article online at http://www.black-
well-synergy.com:
Table S1. Relationship between the prevalence
of methicillin-resistant Staphylococcus aureus
(MRSA) and the weighted and adjusted use of
antimicrobial agents.
Table S2. Relationships between the preval-
ence of methicillin-resistant Staphylococcus aureus
(MRSA) and key infection control parameters.
Table S3. Relationships between the preval-
ence of methicillin-resistant Staphylococcus aureus
(MRSA) and stafﬁng levels.
Table S4. Weighted linear regression for meth-
icillin-resistant Staphylococcus aureus (MRSA) and
stafﬁng levels ⁄ training.
Table S5. Weighted linear regression for meth-
icillin-resistant Staphylococcus aureus (MRSA) and
MRSA screening.
Table S6. Weighted linear regression for meth-
icillin-resistant Staphylococcus aureus (MRSA) and
MRSA infection control policy recommendations.
Table S7. Weighted linear regression for meth-
icillin-resistant Staphylococcus aureus (MRSA) and
infection control guidelines ⁄ feedback.
REFERENCES
1. Perencevich EN, Hartley DM. Of models and methods: our
analytic armamentarium applied to methicillin-resistant
Staphylococcus aureus. Infect Control Hosp Epidemiol 2005; 26:
594–597.
2. Richet H, Benbachir M, Brown DE et al. Are there
regional variations in the diagnosis, surveillance, and
control of MRSA? Infect Control Hosp Epidemiol 2003; 24:
334–341.
3. Ward MM, Diekema DJ, Yankey JW et al. Implement-
ation of strategies to prevent and control the emergence
and spread of antimicrobial-resistant microorganisms in
US hospitals. Infect Control Hosp Epidemiol 2005; 26:
31–38.
4. Harbarth S. Control of nosocomial methicillin-resistant
Staphylococcus aureus: where shall we send our hospital
director next time? Infect Control Hosp Epidemiol 2005; 24:
314–316.
5. Bonten MJM, Austin DJ, Lipstich M. Understanding the
spread of antibiotic resistant pathogens in hospitals:
mathematical models as tools for control. Clin Infect Dis
2001; 33: 1739–1746.
6. National Committee for Clinical Laboratory Standards.
Analysis and presentation of cumulative antimicrobial suscep-
tibility test data. Approved guideline, document M39-A2.
Wayne, PA: NCCLS, 2005.
7. Monnet DL. ABC Calc—antibiotic consumption calculator
(Microsoft Excel application), v.2.0. Copenhagen: Statens
Serum Institut, 2004.
8. Anonymous. Anatomical therapeutic chemical (ATC) classiﬁ-
cation index with deﬁned daily doses (DDDs). Oslo: WHO
Collaborating Centre for Drug Statistics Methodology,
2004.
9. Pittet D, Mourouga P, Perneger TV. Compliance with
handwashing in a teaching hospital. Infection Control
Program. Ann Intern Med 1999; 130: 126–130.
10. Vos MC, Verbrugh HA. MRSA: we can overcome, but who
will lead the battle? Infect Control Hosp Epidemiol 2005; 26:
117–120.
11. Fridkin SK, Pear SM, Williamson TH, Galgiani JN, Jarvis
WR. The role of understafﬁng in central venous catheter-
associated bloodstream infections. Infect Control Hosp Epi-
demiol 1996; 17: 150–158.
12. White RL. How do measurements of antibiotic consump-
tion relate to antibiotic resistance? In: Gould IM, van der
Meer JWM, eds, Antibiotic policies; theory and practice. New
York: Kluwer, 2005; 75–103.
13. Carmeli Y, Castro J, Eliopoulos GM, Samore MH. Clinical
isolation and resistance patterns of and superinfection
with 10 nosocomial pathogens after treatment with ceftri-
axone versus ampicillin–sulbactam. Antimicrob Agents
Chemother 2001; 45: 275–279.
14. Campillo B, Dupeyron C, Richardet JP. Epidemiology of
hospital-acquired infections in cirrhotic patients: effect
of carriage of methicillin-resistant Staphylococcus aure-
us and inﬂuence of previous antibiotic therapy and
norﬂoxacin prophylaxis. Epidemiol Infect 2001; 127: 443–
450.
15. Harbarth S, Liassine N, Dharan S, Herrault P, Auckent-
haler R, Pittet D. Risk factors for persistent carriage of
methicillin-resistant Staphylococcus aureus. Clin Infect Dis
2000; 31: 1380–1385.
16. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli
Y. Fluoroquinolones and the risk for methicillin-resistant
Staphylococcus aureus in hospitalized patients. Emerg Infect
Dis 2003; 9: 1415–1422.
17. Monnet DL, MacKenzie FM, Lo´pez-Lozano J et al. Anti-
microbial drug use and methicillin-resistant Staphylococcus
aureus, Aberdeen, 1996–2000. Emerg Infect Dis 2004; 10:
1432–1440.
MacKenzie et al. MRSA in European hospitals 275
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 269–276
18. Muller AA, Mauny F, Bertin M et al. Relationship between
spread of methicillin-resistant Staphylococcus aureus and
antimicrobial use in a French university hospital. Clin
Infect Dis 2003; 36: 971–978.
19. Crowcroft NS, Ronveaux O, Monnet DL, Mertens R.
Methicillin-resistant Staphylococcus aureus and antimicro-
bial use in Belgian hospitals. Infect Control Hosp Epidemiol
1999; 20: 31–36.
20. Landman D, Chockalingam M, Quale J. Reduction in the
incidence of methicillin-resistant Staphylococcus aureus and
ceftazidime-resistant Klebsiella pneumoniae following
changes in a hospital antibiotic formulary. Clin Infect Dis
1999; 28: 1062–1066.
21. European Antimicrobial Resistance Surveillance System.
EARSS annual report 2001. Bilthoven: National Institute for
Public Health and the Environment, 2001.
276 Clinical Microbiology and Infection, Volume 13 Number 3, March 2007
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 269–276
